Sweden’s Cubase Bio teams up with HeartBeat.bio to advance 3D spatial mapping for heart disease

HomeNewsPartnerships PartnershipsFundingBiotech Sweden’s Cubase Bio teams up with HeartBeat.bio to advance 3D spatial mapping for heart disease By Nurcin Metingil September 11, 2026 0 62 FacebookTwitterWhatsAppLinkedinEmailTelegram Cubase Bio, a Stockholm-based spatial biology company developing technology to map biological systems in true three dimensions, has partnered with Austria’s HeartBeat.bio to advance 3D spatial transcriptomics for cardiovascular drug discovery. This company-specific development has drawn attention from market participants. HomeNewsPartnerships PartnershipsFundingBiotech Sweden’s Cubase Bio teams up with HeartBeat.bio to advance 3D spatial mapping for heart disease By Nurcin Metingil September 11, 2026 0 62 FacebookTwitterWhatsAppLinkedinEmailTelegram Cubase Bio, a Stockholm-based spatial biology company developing technology to map biological systems in true three dimensions, has partnered with Austria’s HeartBeat.bio to advance 3D spatial transcriptomics for cardiovascular drug discovery.The companies have secured approximately €1 million in Eurostars funding for the FACTS-3D project, which will combine Cubase Bio’s proprietary 3D spatial transcriptomics platform with HeartBeat.bio’s human cardiac organoids to study myocardial fibrosis, a key driver of heart failure.The collaboration will allow Cubase Bio to apply its technology to intact 3D cardiac tissue and develop a scalable approach for high-throughput drug screening in 96- and 384-well formats, with the partners aiming to generate insights into disease mechanisms, treatment responses and potential drug targets.Key players involved: Insight Partners, Goldman Sachs Asset Management This development has significant implications for the industry, potentially influencing competitive dynamics, investment patterns, and strategic priorities across the sector. It develops 3D spatial transcriptomics technology designed to map molecular and cellular information within intact biological samples, using sequencing and computational methods to reconstruct spatial organization in three dimensions. Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert CommentaryThis makes our 3D spatial transcriptomics technology a natural fit for high-throughput cardiac drug screening ’, said Malte Kühnemund, CEO of Cubase Bio. Looking AheadFor complete details on this development, refer to the original report from ArcticStartup. Frequently Asked Questions